Thermostable Vaccine Initiative

About Turn Therapeutics

Turn Therapeutics is advancing a pipeline of first-in-class, localized cytokine-modulating therapies, beginning with dermatologic inflammation. The company's mission is to deliver biologic-level efficacy precisely where disease occurs, avoiding the systemic side effects associated with injectable biologics. It has achieved regulatory validation with three FDA clearances for its proprietary wound and dermatology formulations, which support a capital-efficient business model. Turn's lead program, GX-03, is a topical modulator targeting IL-36 and other key cytokines for moderate-to-severe atopic dermatitis (eczema).

Therapeutic Areas